Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

INSIGHTEC ANNOUNCES NEW CATEGORY I CPT® CODE FROM AMA FOR NEURO PROCEDURES USING MR-GUIDED FOCUSED ULTRASOUND
  • USA - English

INSIGHTEC Logo

News provided by

INSIGHTEC

02 Nov, 2023, 15:57 IST

Share this article

Share toX

Share this article

Share toX

New code means acceptance of focused ultrasound technology as mainstream treatment, leading to standardized reimbursement for US physicians

HAIFA, Israel and MIAMI, Nov. 2, 2023 /CNW/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that the editorial panel of the American Medical Association (AMA) approved their application to establish a new Category (Cat) I Current Procedural Terminology (CPT®) code to facilitate reimbursement for MR-guided focused ultrasound (MRgFUS) ablation of neurological targets. The Cat I CPT® code will be included in the next CPT® codebook and expected to be effective January 1, 2025.

"Achieving a Cat I CPT® code is a tremendous milestone for not only Insightec, but for patients and physicians across the United States," explains Maurice R. Ferré, MD, CEO and chairman of the board of Insightec. "We've long known that focused ultrasound has a significant and valuable role in treating patients with neurological disorders. The approval of this code is further validation and indication of the broader adoption of focused ultrasound, and assurance that those who provide this critical service will receive consistent reimbursement."

"This approval can also lead to expanded access to focused ultrasound for US patients," says Dee Kolanek, vice president of market access and reimbursement for Insightec. "Thanks to the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) who supported the application, this code now gives physicians a definitive reimbursement and, we believe, will have a positive impact on utilization going forward."

Focused ultrasound, which was pioneered by Insightec, is FDA approved to treat essential tremor and Parkinsonian tremor. The procedure is performed in a single, outpatient procedure with many patients showing immediate improvement of tremor in the treated hand with minimal or no complications. There are currently over 50 treatment centers across the United States and more than 125 treatment centers around the world using Insightec's Exablate® Neuro platform.

About Insightec

Insightec is a global healthcare company creating the next generation of patient care by realizing the therapeutic power of acoustic energy. The company's Exablate Neuro platform focuses sound waves, safely guided by MRI, to provide tremor treatment to patients with medication-refractory essential tremor and Parkinson's disease. Research for future applications in the neuroscience space is underway in partnership with leading academic and medical institutions. Insightec is headquartered in Haifa, Israel, and Miami, with offices in Dallas, Shanghai, and Tokyo.

Follow us on Facebook, LinkedIn and Twitter or visit www.insightec.com for more information.

Forward-looking Statements:

This document contains forward-looking statements regarding, among other things, plans, expectations, and future events. In some cases, forward-looking statements can be identified by the following words: "may," "can," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "promise," "continue," "ongoing," or the negative of these terms. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. Any forward-looking statement is based on information available to Insightec as of the date of the statement. All written or oral forward-looking statements attributable to Insightec are qualified by this caution. Insightec does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Insightec's expectations.

"Exablate," and "Exablate Neuro," as well as the "INSIGHTEC" logo, whether standing alone or in connection with the word "Insightec", are protected trademarks of Insightec.

Insightec Media Contact:
G&S Business Communications for Insightec
Marjani Williams
[email protected]
(312) 648-6700, ext.2108

Photo - https://mma.prnewswire.com/media/1699588/4172473/Insightec_Logo.jpg

SOURCE INSIGHTEC

Modal title

Also from this source

Insightec's Incisionless Focused Ultrasound Therapy Successfully Treats Downton Abbey Creator Lord Julian Fellowes for Essential Tremor

Insightec's Incisionless Focused Ultrasound Therapy Successfully Treats Downton Abbey Creator Lord Julian Fellowes for Essential Tremor

Insightec, a global healthcare innovator pioneering the use of focused ultrasound to transform patient care, today announced that Lord Julian...

Insightec Announces FDA Approval of Staged Bilateral Focused Ultrasound Treatment for Parkinson's Disease

Insightec Announces FDA Approval of Staged Bilateral Focused Ultrasound Treatment for Parkinson's Disease

Insightec, a global healthcare innovator dedicated to using focused ultrasound to transform patient care, announced today that the U.S. Food and Drug ...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Medical Equipment

Medical Equipment

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +972-77-2005042
    from 8 AM - 11 PM IL

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Csezh
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italie
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+972-77-2005042
from 8 AM - 11 PM IL
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.